Tom Gallen

Tom Gallen

Managing Editor, Europe

Birmingham, UK

Tom reports and edits European consumer health care industry news and analysis. Leading HBW Insight’s health and wellness coverage in Europe, he has been writing about the sector since 2013. Tom’s main focus is analyzing the strategies of the world's leading consumer healthcare companies, their business performance, plans and product portfolios. He also reports on regulatory topics such as novel foods and prescription-to-OTC switches.

Latest from Tom Gallen

Haleon Sales Up Despite Weaker Cold & Flu Season

UK-based consumer health giant reports organic sales growth of 5.0% in 2024 as gains for its power brands offset a softer cold & flu season, particularly in the US.

Haleon’s US Eroxon Launch Falls Short Of Expectations

Consumer uptake of Eroxon - the first FDA-approved OTC ED treatment available in the US - has been slower than expected, according to Haleon, which says its working with retailers to build awareness.

Red Yeast Rice Supplements Facing EU Ban Following Safety Review

Supplements already under close scrutiny in the EU have been linked to severe adverse effects on the musculoskeletal system and liver, even at low doses.

SFI Expands Distribution Of Brain Health Supplement In Europe

Australia's SFI Health looking to take Equazen omega-3 fatty acids supplement to new markets to capitalize on Europe's fast-growing brain health segment.

Haleon Ready To Partner To Deliver Breakthrough CHC Innovation

Start-ups and individuals working on innovative consumer health concepts, in categories such as pain relief and dietary supplements, have the opportunity to access Haleon's resources and expertise to make their ideas a reality.

Spinach Weight Loss Supplement Fails In EU Health Claim Bid

In its first health claim assessment of 2025, the European Commission has rejected an application by Sweden's Greenleaf for its Appethyl supplement.